Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Nanjing Pharmaceutical Co., Ltd., commonly referred to as Nanjing Pharma, is a prominent player in the pharmaceutical preparation manufacturing industry, headquartered in Nanjing, China. Established in 1995, the company has made significant strides in developing high-quality pharmaceutical products, focusing on both generic and innovative medications.
With a strong operational presence across various regions in China, Nanjing Pharma excels in producing a diverse range of core products, including injectables, tablets, and capsules. Their commitment to quality and adherence to international standards set them apart in a competitive market.
Recognised for their robust research and development capabilities, Nanjing Pharma has achieved notable milestones, positioning itself as a trusted name in the pharmaceutical sector. The company continues to expand its market reach, driven by a dedication to improving healthcare outcomes globally.
-17 vs industry average
Nanjing Pharmaceutical’s score of 25 is lower than 35% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the most carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Nanjing Pharmaceutical, a Pharmaceutical Preparation Manufacturing company headquartered in CN, reported its 2023 Scope 1 emissions at approximately 4,996,500 kg CO2e and Scope 2 emissions at about 62,636,180 kg CO2e. In 2022, the company's Scope 1 emissions were approximately 5,280,740 kg CO2e, with Scope 2 emissions around 63,969,770 kg CO2e. For 2021, Nanjing Pharmaceutical's Scope 1 emissions were about 4,513,410 kg CO2e and Scope 2 emissions were approximately 55,998,500 kg CO2e. The company has not disclosed Scope 3 emissions data for these years, with specific missing data points for "scope_3/purchased_goods_and_services". Nanjing Pharmaceutical currently has no publicly stated emissions reduction targets or commitments, including Science Based Targets initiative (SBTi) targets or a climate pledge.
No climate goals have been disclosed for Nanjing Pharmaceutical yet.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more